NanoViricides IncNNVC
Price$1.26

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Mar 2026
Net Income -$8.1MTTM through 31 Mar 2026
Free Cash Flow -$7.4MTTM through 31 Mar 2026

Margins

Current

Returns

-88.4%ROE
-79.2%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio3.17x
Net Debt-$3.2Mnet cash position
Cash & Equivalents$3.2M

Quality Metrics

Altman Z-Score-2.28
Piotroski F-Score1 / 9
Earnings-Beat Rate33.3%

Multi-Year Trend

Revenue
'23'24'25
FY2025: $0
Diluted EPS-$0.44TTM
'17'18'21'22'23'24'25
FY2025: $-0.63

Dividend

No dividend

Capital Allocation

R&D Spend$4.6M

Segment Performance

SegmentRevenueYoYOutlook
Pharmaceutical Research and Development$0
View details

The Company continues to focus on clinical trial site readiness and regulatory approvals for NV-387.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.